How  ||| S:0 E:4 ||| WRB
Ebola  ||| S:4 E:10 ||| NNP
virus  ||| S:10 E:16 ||| NN
counters  ||| S:16 E:25 ||| NNS
the  ||| S:25 E:29 ||| DT
interferon  ||| S:29 E:40 ||| JJ
system  ||| S:40 E:47 ||| NN
Zoonotic  ||| S:47 E:56 ||| NNP
transmission  ||| S:56 E:69 ||| NN
of  ||| S:69 E:72 ||| IN
Ebola  ||| S:72 E:78 ||| NNP
virus  ||| S:78 E:84 ||| NN
( ||| S:84 E:85 ||| -LRB-
EBOV ||| S:85 E:89 ||| NNP
)  ||| S:89 E:91 ||| -RRB-
to  ||| S:91 E:94 ||| TO
humans  ||| S:94 E:101 ||| NNS
causes  ||| S:101 E:108 ||| VBZ
a  ||| S:108 E:110 ||| DT
severe  ||| S:110 E:117 ||| JJ
haemorrhagic  ||| S:117 E:130 ||| JJ
fever  ||| S:130 E:136 ||| NN
in  ||| S:136 E:139 ||| IN
afflicted  ||| S:139 E:149 ||| JJ
individuals  ||| S:149 E:161 ||| NNS
with  ||| S:161 E:166 ||| IN
high  ||| S:166 E:171 ||| JJ
case-fatality  ||| S:171 E:185 ||| JJ
rates ||| S:185 E:190 ||| NNS
.  ||| S:190 E:192 ||| .
Neither  ||| S:192 E:200 ||| DT
vaccines  ||| S:200 E:209 ||| NNS
nor  ||| S:209 E:213 ||| CC
therapeutics  ||| S:213 E:226 ||| NNS
are  ||| S:226 E:230 ||| VBP
at  ||| S:230 E:233 ||| IN
present  ||| S:233 E:241 ||| JJ
available  ||| S:241 E:251 ||| JJ
to  ||| S:251 E:254 ||| TO
combat  ||| S:254 E:261 ||| VB
EBOV  ||| S:261 E:266 ||| JJ
infection ||| S:266 E:275 ||| NN
,  ||| S:275 E:277 ||| ,
making  ||| S:277 E:284 ||| VBG
the  ||| S:284 E:288 ||| DT
virus  ||| S:288 E:294 ||| NN
a  ||| S:294 E:296 ||| DT
potential  ||| S:296 E:306 ||| JJ
threat  ||| S:306 E:313 ||| NN
to  ||| S:313 E:316 ||| TO
public  ||| S:316 E:323 ||| JJ
health ||| S:323 E:329 ||| NN
.  ||| S:329 E:331 ||| .
To  ||| S:331 E:334 ||| TO
devise  ||| S:334 E:341 ||| VB
antiviral  ||| S:341 E:351 ||| JJ
strategies ||| S:351 E:361 ||| NNS
,  ||| S:361 E:363 ||| ,
it  ||| S:363 E:366 ||| PRP
is  ||| S:366 E:369 ||| VBZ
important  ||| S:369 E:379 ||| JJ
to  ||| S:379 E:382 ||| TO
understand  ||| S:382 E:393 ||| VB
which  ||| S:393 E:399 ||| WDT
components  ||| S:399 E:410 ||| NNS
of  ||| S:410 E:413 ||| IN
the  ||| S:413 E:417 ||| DT
immune  ||| S:417 E:424 ||| JJ
system  ||| S:424 E:431 ||| NN
could  ||| S:431 E:437 ||| MD
be  ||| S:437 E:440 ||| VB
effective  ||| S:440 E:450 ||| JJ
against  ||| S:450 E:458 ||| IN
EBOV  ||| S:458 E:463 ||| NNP
infection ||| S:463 E:472 ||| NN
.  ||| S:472 E:474 ||| .
The  ||| S:474 E:478 ||| DT
interferon  ||| S:478 E:489 ||| NN
( ||| S:489 E:490 ||| -LRB-
IFN ||| S:490 E:493 ||| NNP
)  ||| S:493 E:495 ||| -RRB-
system  ||| S:495 E:502 ||| NN
constitutes  ||| S:502 E:514 ||| VBZ
a  ||| S:514 E:516 ||| DT
key  ||| S:516 E:520 ||| JJ
innate  ||| S:520 E:527 ||| JJ
defence  ||| S:527 E:535 ||| NN
against  ||| S:535 E:543 ||| IN
viral  ||| S:543 E:549 ||| JJ
infections  ||| S:549 E:560 ||| NNS
and  ||| S:560 E:564 ||| CC
prevents  ||| S:564 E:573 ||| JJ
development  ||| S:573 E:585 ||| NN
of  ||| S:585 E:588 ||| IN
lethal  ||| S:588 E:595 ||| JJ
disease  ||| S:595 E:603 ||| NN
in  ||| S:603 E:606 ||| IN
mice  ||| S:606 E:611 ||| NNS
infected  ||| S:611 E:620 ||| VBN
with  ||| S:620 E:625 ||| IN
EBOV  ||| S:625 E:630 ||| NNP
strains  ||| S:630 E:638 ||| NNS
not  ||| S:638 E:642 ||| RB
adapted  ||| S:642 E:650 ||| VBN
to  ||| S:650 E:653 ||| TO
this  ||| S:653 E:658 ||| DT
host ||| S:658 E:662 ||| NN
.  ||| S:662 E:664 ||| .
Recent  ||| S:664 E:671 ||| JJ
research  ||| S:671 E:680 ||| NN
revealed  ||| S:680 E:689 ||| VBD
that  ||| S:689 E:694 ||| DT
expression  ||| S:694 E:705 ||| NN
of  ||| S:705 E:708 ||| IN
the  ||| S:708 E:712 ||| DT
host  ||| S:712 E:717 ||| NN
cell  ||| S:717 E:722 ||| NN
IFN-inducible  ||| S:722 E:736 ||| FW
transmembrane  ||| S:736 E:750 ||| FW
proteins  ||| S:750 E:759 ||| FW
1-3  ||| S:759 E:763 ||| FW
( ||| S:763 E:764 ||| -LRB-
IFITM1-3 ||| S:764 E:772 ||| NNP
)  ||| S:772 E:774 ||| -RRB-
and  ||| S:774 E:778 ||| CC
tetherin  ||| S:778 E:787 ||| NN
is  ||| S:787 E:790 ||| VBZ
induced  ||| S:790 E:798 ||| VBN
by  ||| S:798 E:801 ||| IN
IFN  ||| S:801 E:805 ||| NNP
and  ||| S:805 E:809 ||| CC
restricts  ||| S:809 E:819 ||| VBZ
EBOV  ||| S:819 E:824 ||| NNP
infection ||| S:824 E:833 ||| NN
,  ||| S:833 E:835 ||| ,
at  ||| S:835 E:838 ||| IN
least  ||| S:838 E:844 ||| JJS
in  ||| S:844 E:847 ||| IN
cell  ||| S:847 E:852 ||| NN
culture  ||| S:852 E:860 ||| NN
model  ||| S:860 E:866 ||| NN
systems ||| S:866 E:873 ||| NNS
.  ||| S:873 E:875 ||| .
IFITMs ||| S:875 E:881 ||| NNP
,  ||| S:881 E:883 ||| ,
tetherin  ||| S:883 E:892 ||| NN
and  ||| S:892 E:896 ||| CC
other  ||| S:896 E:902 ||| JJ
effector  ||| S:902 E:911 ||| JJ
molecules  ||| S:911 E:921 ||| NNS
of  ||| S:921 E:924 ||| IN
the  ||| S:924 E:928 ||| DT
IFN  ||| S:928 E:932 ||| NNP
system  ||| S:932 E:939 ||| NN
could  ||| S:939 E:945 ||| MD
thus  ||| S:945 E:950 ||| RB
pose  ||| S:950 E:955 ||| VB
a  ||| S:955 E:957 ||| DT
potent  ||| S:957 E:964 ||| JJ
barrier  ||| S:964 E:972 ||| NN
against  ||| S:972 E:980 ||| IN
EBOV  ||| S:980 E:985 ||| NNP
spread  ||| S:985 E:992 ||| NN
in  ||| S:992 E:995 ||| IN
humans ||| S:995 E:1001 ||| NNS
.  ||| S:1001 E:1003 ||| .
However ||| S:1003 E:1010 ||| RB
,  ||| S:1010 E:1012 ||| ,
EBOV  ||| S:1012 E:1017 ||| NNP
interferes  ||| S:1017 E:1028 ||| VBZ
with  ||| S:1028 E:1033 ||| IN
signalling  ||| S:1033 E:1044 ||| JJ
events  ||| S:1044 E:1051 ||| NNS
required  ||| S:1051 E:1060 ||| VBN
for  ||| S:1060 E:1064 ||| IN
human  ||| S:1064 E:1070 ||| JJ
cells  ||| S:1070 E:1076 ||| NNS
to  ||| S:1076 E:1079 ||| TO
express  ||| S:1079 E:1087 ||| VB
these  ||| S:1087 E:1093 ||| DT
proteins ||| S:1093 E:1101 ||| NNS
.  ||| S:1101 E:1103 ||| .
Here ||| S:1103 E:1107 ||| RB
,  ||| S:1107 E:1109 ||| ,
we  ||| S:1109 E:1112 ||| PRP
will  ||| S:1112 E:1117 ||| MD
review  ||| S:1117 E:1124 ||| VB
the  ||| S:1124 E:1128 ||| DT
strategies  ||| S:1128 E:1139 ||| NNS
employed  ||| S:1139 E:1148 ||| VBN
by  ||| S:1148 E:1151 ||| IN
EBOV  ||| S:1151 E:1156 ||| NNP
to  ||| S:1156 E:1159 ||| TO
fight  ||| S:1159 E:1165 ||| VB
the  ||| S:1165 E:1169 ||| DT
IFN  ||| S:1169 E:1173 ||| NNP
system ||| S:1173 E:1179 ||| NN
,  ||| S:1179 E:1181 ||| ,
and  ||| S:1181 E:1185 ||| CC
we  ||| S:1185 E:1188 ||| PRP
will  ||| S:1188 E:1193 ||| MD
discuss  ||| S:1193 E:1201 ||| VB
how  ||| S:1201 E:1205 ||| WRB
IFITM  ||| S:1205 E:1211 ||| NNP
proteins  ||| S:1211 E:1220 ||| NNS
and  ||| S:1220 E:1224 ||| CC
tetherin  ||| S:1224 E:1233 ||| NNS
inhibit  ||| S:1233 E:1241 ||| VBP
EBOV  ||| S:1241 E:1246 ||| JJ
infection ||| S:1246 E:1255 ||| NN
.  ||| S:1255 E:1257 ||| .
